Intracoronary urokinase for intracoronary thrombus accumulation complicating percutaneous transluminal coronary angioplasty in acute ischemic syndromes

G. Schieman, Barry Cohen, J. Kozina, J. S. Erickson, R. A. Podolin, K. L. Peterson, J. Ross, M. Buchbinder

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Intracoronary urokinase was used to treat flow-limiting intracoronary thrombus accumulation that complicated successful percutaneous transluminal coronary angioplasty (PTCA) during acute ischemic syndromes in 48 patients who were followed up through the acute phase of their illness. The study group comprised 10 patients with unstable angina pectoris, 18 patients with an evolving acute myocardial infarction, and 20 patients with postinfarction angina. The initial mean percent coronary diameter stenosis for the entire population was 95 ± 7% and decreased with initial PTCA to 41 ± 20% (p < 0.001), with improved corresponding coronary flow by Thrombolysis in Myocardial Infarction trial (TIMI) grade. However, thrombus accumulation then resulted in a significant increase in percent diameter stenosis to 83 ± 17% (p < 0.001); a corresponding significant reduction in coronary flow also occurred by TIMI grade. After administration of intracoronary urokinase (mean dose, 141,000 units; range, 100,000-250,000 units during an average period of 34 minutes), with additional PTCA, mean percent diameter stenosis significantly decreased to 34 ± 17% (p < 0.001); a correspondingly significant improvement in mean coronary flow by TIMI grade occurred to 2.9 ± 0.2. Overall, the angiographic success rate was 90%. There were no ischemic events requiring repeat PTCA and no procedure-related myocardial infarctions or deaths before hospital discharge. One patient was referred for urgent coronary artery bypass graft surgery after a successful PTCA. Plasma fibrinogen levels were obtained in 15 patients, and in no patient was the level below normal for our laboratory. Angiographic follow-up was obtained in 79% of patients (average time 30 days with 63% of all patients studied before discharge), and in no patient was there angiographic evidence of reocclusion, although two patients showed angiographic evidence of stenosis; improved vessel percent stenosis persisted, averaging 32 ± 17%. In all patients studied, the coronary flow was TIMI grade 3 at follow-up. Thus, in patients with acute ischemic syndromes with flow-limiting intracoronary thrombus accumulation that complicated PTCA, intracoronary urokinase with repeated PTCA proved to be highly effective in restoring vessel patency and avoiding early complications.

Original languageEnglish (US)
Pages (from-to)2052-2060
Number of pages9
JournalCirculation
Volume82
Issue number6
DOIs
StatePublished - Jan 1 1990
Externally publishedYes

Fingerprint

Coronary Balloon Angioplasty
Urokinase-Type Plasminogen Activator
Thrombosis
Myocardial Infarction
Pathologic Constriction
Coronary Stenosis
Unstable Angina
Coronary Artery Bypass
Fibrinogen

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Schieman, G. ; Cohen, Barry ; Kozina, J. ; Erickson, J. S. ; Podolin, R. A. ; Peterson, K. L. ; Ross, J. ; Buchbinder, M. / Intracoronary urokinase for intracoronary thrombus accumulation complicating percutaneous transluminal coronary angioplasty in acute ischemic syndromes. In: Circulation. 1990 ; Vol. 82, No. 6. pp. 2052-2060.
@article{eb53b4e578e149e4be518cdfd0b24680,
title = "Intracoronary urokinase for intracoronary thrombus accumulation complicating percutaneous transluminal coronary angioplasty in acute ischemic syndromes",
abstract = "Intracoronary urokinase was used to treat flow-limiting intracoronary thrombus accumulation that complicated successful percutaneous transluminal coronary angioplasty (PTCA) during acute ischemic syndromes in 48 patients who were followed up through the acute phase of their illness. The study group comprised 10 patients with unstable angina pectoris, 18 patients with an evolving acute myocardial infarction, and 20 patients with postinfarction angina. The initial mean percent coronary diameter stenosis for the entire population was 95 ± 7{\%} and decreased with initial PTCA to 41 ± 20{\%} (p < 0.001), with improved corresponding coronary flow by Thrombolysis in Myocardial Infarction trial (TIMI) grade. However, thrombus accumulation then resulted in a significant increase in percent diameter stenosis to 83 ± 17{\%} (p < 0.001); a corresponding significant reduction in coronary flow also occurred by TIMI grade. After administration of intracoronary urokinase (mean dose, 141,000 units; range, 100,000-250,000 units during an average period of 34 minutes), with additional PTCA, mean percent diameter stenosis significantly decreased to 34 ± 17{\%} (p < 0.001); a correspondingly significant improvement in mean coronary flow by TIMI grade occurred to 2.9 ± 0.2. Overall, the angiographic success rate was 90{\%}. There were no ischemic events requiring repeat PTCA and no procedure-related myocardial infarctions or deaths before hospital discharge. One patient was referred for urgent coronary artery bypass graft surgery after a successful PTCA. Plasma fibrinogen levels were obtained in 15 patients, and in no patient was the level below normal for our laboratory. Angiographic follow-up was obtained in 79{\%} of patients (average time 30 days with 63{\%} of all patients studied before discharge), and in no patient was there angiographic evidence of reocclusion, although two patients showed angiographic evidence of stenosis; improved vessel percent stenosis persisted, averaging 32 ± 17{\%}. In all patients studied, the coronary flow was TIMI grade 3 at follow-up. Thus, in patients with acute ischemic syndromes with flow-limiting intracoronary thrombus accumulation that complicated PTCA, intracoronary urokinase with repeated PTCA proved to be highly effective in restoring vessel patency and avoiding early complications.",
author = "G. Schieman and Barry Cohen and J. Kozina and Erickson, {J. S.} and Podolin, {R. A.} and Peterson, {K. L.} and J. Ross and M. Buchbinder",
year = "1990",
month = "1",
day = "1",
doi = "10.1161/01.CIR.82.6.2052",
language = "English (US)",
volume = "82",
pages = "2052--2060",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

Intracoronary urokinase for intracoronary thrombus accumulation complicating percutaneous transluminal coronary angioplasty in acute ischemic syndromes. / Schieman, G.; Cohen, Barry; Kozina, J.; Erickson, J. S.; Podolin, R. A.; Peterson, K. L.; Ross, J.; Buchbinder, M.

In: Circulation, Vol. 82, No. 6, 01.01.1990, p. 2052-2060.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intracoronary urokinase for intracoronary thrombus accumulation complicating percutaneous transluminal coronary angioplasty in acute ischemic syndromes

AU - Schieman, G.

AU - Cohen, Barry

AU - Kozina, J.

AU - Erickson, J. S.

AU - Podolin, R. A.

AU - Peterson, K. L.

AU - Ross, J.

AU - Buchbinder, M.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Intracoronary urokinase was used to treat flow-limiting intracoronary thrombus accumulation that complicated successful percutaneous transluminal coronary angioplasty (PTCA) during acute ischemic syndromes in 48 patients who were followed up through the acute phase of their illness. The study group comprised 10 patients with unstable angina pectoris, 18 patients with an evolving acute myocardial infarction, and 20 patients with postinfarction angina. The initial mean percent coronary diameter stenosis for the entire population was 95 ± 7% and decreased with initial PTCA to 41 ± 20% (p < 0.001), with improved corresponding coronary flow by Thrombolysis in Myocardial Infarction trial (TIMI) grade. However, thrombus accumulation then resulted in a significant increase in percent diameter stenosis to 83 ± 17% (p < 0.001); a corresponding significant reduction in coronary flow also occurred by TIMI grade. After administration of intracoronary urokinase (mean dose, 141,000 units; range, 100,000-250,000 units during an average period of 34 minutes), with additional PTCA, mean percent diameter stenosis significantly decreased to 34 ± 17% (p < 0.001); a correspondingly significant improvement in mean coronary flow by TIMI grade occurred to 2.9 ± 0.2. Overall, the angiographic success rate was 90%. There were no ischemic events requiring repeat PTCA and no procedure-related myocardial infarctions or deaths before hospital discharge. One patient was referred for urgent coronary artery bypass graft surgery after a successful PTCA. Plasma fibrinogen levels were obtained in 15 patients, and in no patient was the level below normal for our laboratory. Angiographic follow-up was obtained in 79% of patients (average time 30 days with 63% of all patients studied before discharge), and in no patient was there angiographic evidence of reocclusion, although two patients showed angiographic evidence of stenosis; improved vessel percent stenosis persisted, averaging 32 ± 17%. In all patients studied, the coronary flow was TIMI grade 3 at follow-up. Thus, in patients with acute ischemic syndromes with flow-limiting intracoronary thrombus accumulation that complicated PTCA, intracoronary urokinase with repeated PTCA proved to be highly effective in restoring vessel patency and avoiding early complications.

AB - Intracoronary urokinase was used to treat flow-limiting intracoronary thrombus accumulation that complicated successful percutaneous transluminal coronary angioplasty (PTCA) during acute ischemic syndromes in 48 patients who were followed up through the acute phase of their illness. The study group comprised 10 patients with unstable angina pectoris, 18 patients with an evolving acute myocardial infarction, and 20 patients with postinfarction angina. The initial mean percent coronary diameter stenosis for the entire population was 95 ± 7% and decreased with initial PTCA to 41 ± 20% (p < 0.001), with improved corresponding coronary flow by Thrombolysis in Myocardial Infarction trial (TIMI) grade. However, thrombus accumulation then resulted in a significant increase in percent diameter stenosis to 83 ± 17% (p < 0.001); a corresponding significant reduction in coronary flow also occurred by TIMI grade. After administration of intracoronary urokinase (mean dose, 141,000 units; range, 100,000-250,000 units during an average period of 34 minutes), with additional PTCA, mean percent diameter stenosis significantly decreased to 34 ± 17% (p < 0.001); a correspondingly significant improvement in mean coronary flow by TIMI grade occurred to 2.9 ± 0.2. Overall, the angiographic success rate was 90%. There were no ischemic events requiring repeat PTCA and no procedure-related myocardial infarctions or deaths before hospital discharge. One patient was referred for urgent coronary artery bypass graft surgery after a successful PTCA. Plasma fibrinogen levels were obtained in 15 patients, and in no patient was the level below normal for our laboratory. Angiographic follow-up was obtained in 79% of patients (average time 30 days with 63% of all patients studied before discharge), and in no patient was there angiographic evidence of reocclusion, although two patients showed angiographic evidence of stenosis; improved vessel percent stenosis persisted, averaging 32 ± 17%. In all patients studied, the coronary flow was TIMI grade 3 at follow-up. Thus, in patients with acute ischemic syndromes with flow-limiting intracoronary thrombus accumulation that complicated PTCA, intracoronary urokinase with repeated PTCA proved to be highly effective in restoring vessel patency and avoiding early complications.

UR - http://www.scopus.com/inward/record.url?scp=0025607315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025607315&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.82.6.2052

DO - 10.1161/01.CIR.82.6.2052

M3 - Article

C2 - 2242529

AN - SCOPUS:0025607315

VL - 82

SP - 2052

EP - 2060

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 6

ER -